Dangerous Ideas In Drug Development

Join us in this episode with Dr Oksana Zdanska, hearing about her amazing journey from Czech Rep. to Sydney's shores, working in Phase 1 at TKCC and completing her PhD on the patient lived experience. We also hear about her work at Immvirx, which is developing several viral oncololytic RNA therapies for cancers with unmet needs.

Today we are joined by Dr Debora Barton and our very own Head of Nuclear Medicine, Dr Louise Emmett to dive into the world of radionuclide therapy! We learn about how we can move forward without the old cookie cutter approach, how we can alter the paradigm and create a new force for change in nuclear cancer therapy and imaging. We hear about Full Life Therapeutics’ radio ligand discovery platform and in-house actinium production capabilities.

In today's episode we are joined by Dr Lawrence Hamann from Interdict Bio! We hear about bioavailable small molecule drugs that can inhibit ribosomal protein synthesis in MYC-dependent cancers. We also learn some tips for people looking to get into a drug development career!

This episode join us with Prof Neil Fleshner, a Toronto based urology expert for a deep dive into his fascinating career! We'll hear about his early medical days, launching a radio-ligand start-up leading to a +billion dollar buyout, as well as some advice for others interested in the space!

Talk 1: Dr Natalie Cook, The Christie NHS Foundation Trust - Unknown Primary, Known Target: The Agnostic Approach to Precision OncologyTalk 2: A/Prof Jia (Jenny) Liu, St Vincent’s Hospital Sydney -PANNACOTA Final Analysis – Synergies from liquid biopsy and a phase 1 networkTalk 3: Dr Udit Nindra, Wollongong and Liverpool Hospitals - Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER studyTalk 4: Prof Aaron Hanson, Princess Alexandra Hospital Brisbane - Patient Reported Outcomes toolkit for Phase I trialsTalk 5: Dr Rachel Galimidi, Garvan Institute of Medical Research - Discovery and translation, trials and tribulations

Talk 1: Prof Yuxiang Ma, Sun Yat-sen University Cancer Center - Drug development and early phase clinical trials in China, insights from Sun Yat Sen Cancer CentreTalk 2: Prof Ben Tran, Peter MacCallum Cancer Center - T-cell Engagers in Solid Tumours

Talk 1: Prof Tim Yap, MD Anderson Cancer Center - Project Optimus: Reforming dose optimization in early phase clinical trialsTalk 2: Dr Anthony Rodrigues, St Vincent’s Hospital Sydney -Balancing wellbeing in a phase 1 unit for coordinators and cliniciansTalk 3: A/Prof Hao Wen Sim, Chris O'Brien Lifehouse, NHMRC Clinical Trials Centre - Update on Bayesian Designs for Phase 1 Trials

Join us as we bring the year to a close by chatting with Dr Rob Lentz from Natera about how circulating tumour DNA testing can inform better treatment decisions in the clinic. We hear about the power of ctDNA alongside reference tumour informed testing and the latest data supporting it's use in GI as well as many other cancers.

Join us this episode as we talk with Artera, a company leading in the AI space with personalised prognostic insights in cancer care. We learn about this fascinating development of AI in digital pathology which can be rolled out across demographics with predictive applications in prostate and other cancer streams.

Talk 1: Maria Mury, Cancer Institute New South Wales: CINSW, supporting clinical trials and cancer careTalk 2: Dr Matthew Krebs, Manchester Cancer Research Centre: Practical aspects on new generation precision medicine in 2025